Resistin As a Potential Marker of Renal Disease in Lupus Nephritis

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2014 Oct 28

PMID 25345756

Citations 23

Authors

J Hutcheson

Y Ye

J Han

C Arriens

R Saxena

Q-Z Li

C Mohan

T Wu

Affiliations

Soon will be listed here.

Abstract

Systemic lupus erythematosus (SLE) and lupus nephritis (LN) have strong concomitance with cardiovascular disease that cannot be explained fully by typical risk factors. We examined the possibility that serum or urine expression of adipokines may act as biomarkers for LN, as these proteins have been associated previously with cardiovascular disease as well as SLE. Antibody arrays were performed on serum and urine from lupus patients and matched controls using a cross-sectional study design. From the initial array-based screening data of 15 adipokines, adiponectin, leptin and resistin were selected for validation by enzyme-linked immunosorbent assay (ELISA). Correlations were determined between adipokine expression levels and measures of disease activity or lupus nephritis. The expression of adiponectin and resistin was increased in both sera and urine from LN patients, while leptin was increased in LN patient sera, compared to matched controls. Serum resistin, but not urine resistin, was correlated with measures of renal dysfunction in LN. Serum resistin expression may be useful as a marker of renal dysfunction in patients with LN, although longitudinal studies are warranted. Further studies are necessary to determine if resistin has functional consequences in LN.

Citing Articles

Lupus Nephritis from Pathogenesis to New Therapies: An Update.

Roveta A, Parodi E, Brezzi B, Tunesi F, Zanetti V, Merlotti G Int J Mol Sci. 2024; 25(16).

PMID: 39201667 PMC: 11354900. DOI: 10.3390/ijms25168981.

Lupus Nephritis Biomarkers: A Critical Review.

Alduraibi F, Tsokos G Int J Mol Sci. 2024; 25(2).

PMID: 38255879 PMC: 10815779. DOI: 10.3390/ijms25020805.

Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients.

Romejko K, Rymarz A, Szamotulska K, Bartoszewicz Z, Rozmyslowicz T, Niemczyk S Cells. 2023; 12(7).

PMID: 37048072 PMC: 10093733. DOI: 10.3390/cells12070999.

High serum leptin and adiponectin levels as biomarkers of disease progression in Egyptian patients with active systemic lupus erythematosus.

Kamel S, Abdel Azeem Abd Elazeem M, Mohamed R, Kamel M, Abdel Aleem Abdelaleem E Int J Immunopathol Pharmacol. 2023; 37:3946320231154988.

PMID: 36718110 PMC: 9893074. DOI: 10.1177/03946320231154988.

Non-Traditional Pro-Inflammatory and Pro-Atherosclerotic Risk Factors Related to Systemic Lupus Erythematosus.

Richter P, Cardoneanu A, Rezus C, Burlui A, Rezus E Int J Mol Sci. 2022; 23(20).

PMID: 36293458 PMC: 9604037. DOI: 10.3390/ijms232012604.

References

Lartigue A, Colliou N, Calbo S, Francois A, Jacquot S, Arnoult C . Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. J Immunol. 2009; 183(10):6207-16. DOI: 10.4049/jimmunol.0803219. View

Lago F, Dieguez C, Gomez-Reino J, Gualillo O . Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 2007; 3(12):716-24. DOI: 10.1038/ncprheum0674. View

Davis L, Hutcheson J, Mohan C . The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res. 2011; 31(10):781-9. PMC: 3189549. DOI: 10.1089/jir.2011.0047. View

Katz P, Yazdany J, Julian L, Trupin L, Margaretten M, Yelin E . Impact of obesity on functioning among women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011; 63(10):1357-64. PMC: 3183275. DOI: 10.1002/acr.20526. View

Kipen Y, Briganti E, Strauss B, Littlejohn G, Morand E . Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus. Rheumatology (Oxford). 1999; 38(1):59-65. DOI: 10.1093/rheumatology/38.1.59. View

El Magadmi M, Ahmad Y, Turkie W, Yates A, Sheikh N, Bernstein R . Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006; 33(1):50-6. View

Hauner H . Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc. 2005; 64(2):163-9. DOI: 10.1079/pns2005428. View

Almehed K, Forsblad dElia H, Bokarewa M, Carlsten H . Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(1):R15. PMC: 2374439. DOI: 10.1186/ar2366. View

Chung C, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P . High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2006; 66(2):208-14. PMC: 1798504. DOI: 10.1136/ard.2006.054973. View

10.

Brown H, Lock H, Wolfs T, Buurman W, Sacks S, Robson M . Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2. J Am Soc Nephrol. 2007; 18(6):1732-9. DOI: 10.1681/ASN.2006060634. View

11.

Al M, Ng L, Tyrrell P, Bargman J, Bradley T, Silverman E . Adipokines as novel biomarkers in paediatric systemic lupus erythematosus. Rheumatology (Oxford). 2009; 48(5):497-501. DOI: 10.1093/rheumatology/kep030. View

12.

Berg A, Scherer P . Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96(9):939-49. DOI: 10.1161/01.RES.0000163635.62927.34. View

13.

Cumin F, Baum H, Levens N . Mechanism of leptin removal from the circulation by the kidney. J Endocrinol. 1998; 155(3):577-85. DOI: 10.1677/joe.0.1550577. View

14.

Yoshino T, Kusunoki N, Tanaka N, Kaneko K, Kusunoki Y, Endo H . Elevated serum levels of resistin, leptin, and adiponectin are associated with C-reactive protein and also other clinical conditions in rheumatoid arthritis. Intern Med. 2011; 50(4):269-75. DOI: 10.2169/internalmedicine.50.4306. View

15.

Dessein P, Norton G, Woodiwiss A, Solomon A . Independent relationship between circulating resistin concentrations and endothelial activation in rheumatoid arthritis. Ann Rheum Dis. 2013; 72(9):1586-8. DOI: 10.1136/annrheumdis-2013-203587. View

16.

Jamaluddin M, Weakley S, Yao Q, Chen C . Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2011; 165(3):622-32. PMC: 3315035. DOI: 10.1111/j.1476-5381.2011.01369.x. View

17.

Kawamura R, Doi Y, Osawa H, Ninomiya T, Hata J, Yonemoto K . Circulating resistin is increased with decreasing renal function in a general Japanese population: the Hisayama Study. Nephrol Dial Transplant. 2010; 25(10):3236-40. DOI: 10.1093/ndt/gfq155. View

18.

Park S, Carrero J, Lindholm B, Stenvinkel P . Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. Clin Nephrol. 2009; 72(2):87-96. DOI: 10.5414/cnp72087. View

19.

Hama H, Saito A, Takeda T, Tanuma A, Xie Y, Sato K . Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology. 2004; 145(8):3935-40. DOI: 10.1210/en.2004-0074. View

20.

Tarkowski A, Bjersing J, Shestakov A, Bokarewa M . Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2009; 14(6B):1419-31. PMC: 3829009. DOI: 10.1111/j.1582-4934.2009.00899.x. View